Results 151 to 160 of about 11,803,710 (238)
Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes +7 more
wiley +1 more source
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam +3 more
wiley +1 more source
Granzyme K<sup>+</sup> CD8 T cells in autoimmunity. [PDF]
Jonsson AH.
europepmc +1 more source
CD93—An emerging vascular target in cancer therapy
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira +3 more
wiley +1 more source
Bruton tyrosine kinase inhibitors and cardiovascular adverse events
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli +4 more
wiley +1 more source
Abstract Acute lung injury (ALI) is a serious clinical condition with high morbidity and mortality rates. Current ALI treatments have limitations. Natural products from traditional Chinese medicine (TCM) exhibit multi‐component, multi‐target and multi‐pathway regulatory properties with good safety, making them promising candidates for ALI treatment ...
Cheng Luo +10 more
wiley +1 more source
Koumine binds IGF2BP3 and promotes its proteasomal degradation, reducing m6A on EED mRNA, accelerating EED decay, lowering H3K27me3, and promoting IRF transcription, thereby restoring MHC‐I and enhancing CD8+ T cell killing. ABSTRACT Resistance to immune checkpoint blockade in gastric cancer often arises from defective antigen presentation due to MHC‐I
Qiu Hongqiang +10 more
wiley +1 more source
Intravenous (IV) or intratumoral (IT) cetuximab distribution in A431 tumor (essence of Figure 2). ABSTRACT Near‐infrared photoimmunotherapy (NIR‐PIT) is a new type of cancer treatment that specifically kills target cells while sparing normal tissue. This treatment induces cancer cell death by activating a photoreactive dye with near‐infrared light in ...
Miyu Kano +9 more
wiley +1 more source
SLAMF6 recruits SHP‐2 to activate STAT1, upregulates CXCL10 and PD‐L1, promotes CD8+T cell infiltration, and enhances the efficacy of anti‐PD‐L1 therapy. ABSTRACT As a T‐cell receptor co‐stimulatory protein, signaling lymphocyte activation molecule family 6 (SLAMF6) is a member of the immune cell activating receptor family and is expressed on T cells ...
Yu Wu +8 more
wiley +1 more source
Immune surveillance of residual leukemic stem cells after tyrosine kinase inhibitor discontinuation involves coordinated NK‐cell, CTL, Treg, pDC, and neutrophil activity that predicts treatment‐free remission, while exhausted CTLs and Treg expansion predict relapse in chronic myeloid leukemia.
Hiroshi Ureshino, Shinya Kimura
wiley +1 more source

